Corcept Q4/FY2024: Revenue $675M (+40%), Net Income $141M; Guides 2025 $900-950M

CORCEPT THERAPEUTICS INC

2024-FY EPS reported $1.23 revenue$675,040,000

Q4 revenue $181.9M vs $135.4M YoY; FY revenue $675.0M (+40% YoY).
FY net income $141.2M ($1.23 diluted EPS) vs $106.1M ($0.94) in 2023.
2025 revenue guidance $900-$950M; cash and investments $603.2M at Dec 31, 2024.
NDA submitted for relacorilant for hypercortisolism; ROSELLA Phase 3 data expected this quarter.
DAZALS Phase 2 in ALS missed primary endpoint; showed survival benefit (0 vs 5 deaths at 24 weeks, p=0.02).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.